Chimerix Inc (CMRX): Ernest Mario , director of Chimerix Inc purchased 50,000 shares on Jun 24, 2016. The Insider buying transaction was reported by the company on Jun 28, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.70 per share for a total value of $184,845.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 28, 2016, M Michelle Berrey (CEO) purchased 13,188 shares at $3.69 per share price.On May 16, 2016, Ernest Mario (director) purchased 10,000 shares at $4.53 per share price.Also, On Mar 2, 2016, Timothy Wollaeger (director) purchased 10,000 shares at $4.61 per share price.On Mar 2, 2016, Martha J Demski (director) purchased 10,000 shares at $4.89 per share price.
Shares of Chimerix Inc (CMRX) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -0.17 points or -4.56% at $3.56 with 12,38,377 shares getting traded. Post opening the session at $3.7, the shares hit an intraday low of $3.495 and an intraday high of $3.72 and the price vacillated in this range throughout the day. The company has a market cap of $165 M and the number of outstanding shares has been calculated to be 4,62,13,134 shares. The 52-week high of Chimerix Inc is $58.04 and the 52-week low is $3.495.
Chimerix Inc. a biopharmaceutical company dedicated to discovering developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound brincidofovir (BCV CMX001) which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient orally administered dosing regimens. In addition it has an active discovery program focusing on viral targets. CMX157 is its second clinical-stage nucleotide analog uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug tenofovir. Tenofovir marketed under the brand name Viread and in multiple fixed-dose combinations is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered developed and selected a clinical candidate CMX669 for BK virus and cytomegalovirus (CMV).